CURI

On the surface CURI looks like a turnaround: FY2025 revenue jumped 40% to $71.7M, operating loss narrowed 45% to -$7.3M, net loss halved to -$6.4M, and operating cash flow grew 60% to $13.1M against only $102K of capex — real free cash flow from an asset-light 6,000-title factual-content library. The balance sheet is clean: $18.3M cash (up 134%), $41.5M equity versus $34.2M liabilities (0.83x), and no meaningful debt. At $2.91 (P/S 2.4, ~7.6% FCF yield) that is not an expensive setup, and the $22M of dividends paid works out to a headline yield north of 12%.

The problem is the quality of the growth. The MD&A shows the entire revenue beat came from Content Licensing, which exploded 326% from $7.8M to $33.2M, while the core Direct Business — the recurring subscription engine — actually declined 13% to $33.6M. Content licensing is lumpy, deal-driven and far less durable than subscription revenue, so the '40% growth' masks erosion in the business that should command the multiple. Management's own risk factors flag the difficulty of attracting and retaining users, prior subscriber losses when a Bundled Distribution partner terminated in 2022, and heavy competition from MVPDs and SVOD services.